PubMed:22615783
Annnotations
test-210614
Id | Subject | Object | Predicate | Lexical cue | proteinmutation |
---|---|---|---|---|---|
22615783_0 | 992-998 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_1 | 845-851 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_2 | 644-650 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_3 | 528-534 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_4 | 281-287 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_5 | 98-104 | ProteinMutation | denotes | G2019S | rs34637584 |
PubTator4TogoVar
Id | Subject | Object | Predicate | Lexical cue | proteinmutation |
---|---|---|---|---|---|
22615783_0 | 992-998 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_1 | 845-851 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_2 | 644-650 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_3 | 528-534 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_4 | 281-287 | ProteinMutation | denotes | G2019S | rs34637584 |
22615783_5 | 98-104 | ProteinMutation | denotes | G2019S | rs34637584 |
c_corpus
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 5-10 | PR:Q5S006 | denotes | LRRK2 |
T2 | 5-10 | PR:000003033 | denotes | LRRK2 |
T3 | 5-10 | PR:Q5S007 | denotes | LRRK2 |
T4 | 56-61 | CHEBI:30216 | denotes | alpha |
T5 | 56-77 | D000080874 | denotes | alpha-synucleinopathy |
T6 | 56-77 | D000080874 | denotes | alpha-synucleinopathy |
T9 | 81-86 | 10090 | denotes | mouse |
T10 | 81-86 | D051379 | denotes | mouse |
T11 | 87-92 | UBERON:6110636 | denotes | brain |
T12 | 87-92 | UBERON:0000955 | denotes | brain |
T13 | 105-113 | SO:0000109 | denotes | mutation |
T14 | 133-140 | GO:0003675 | denotes | protein |
T18 | 133-140 | SO:0000104 | denotes | protein |
T17 | 133-140 | PR:000000001 | denotes | protein |
T15 | 133-140 | CHEBI:36080 | denotes | protein |
T16 | 133-140 | CHEBI:11122 | denotes | protein |
T20 | 141-148 | 6308 | denotes | leucine |
T21 | 141-148 | SO:0001437 | denotes | leucine |
T19 | 141-148 | CHEBI:15603 | denotes | leucine |
T22 | 141-148 | D007930 | denotes | leucine |
T23 | 141-148 | CHEBI:25017 | denotes | leucine |
T24 | 141-148 | D007930 | denotes | leucine |
T25 | 154-160 | SO:0001068 | denotes | repeat |
T26 | 171-176 | PR:Q5S006 | denotes | LRRK2 |
T27 | 171-176 | PR:000003033 | denotes | LRRK2 |
T28 | 171-176 | PR:Q5S007 | denotes | LRRK2 |
T33 | 237-256 | D010300 | denotes | Parkinson's disease |
T34 | 237-256 | D010300 | denotes | Parkinson's disease |
T37 | 275-280 | PR:Q5S006 | denotes | LRRK2 |
T38 | 275-280 | PR:000003033 | denotes | LRRK2 |
T39 | 275-280 | PR:Q5S007 | denotes | LRRK2 |
T40 | 289-297 | CHEBI:78059 | denotes | carriers |
T41 | 353-360 | D004194 | denotes | disease |
T42 | 353-360 | D004194 | denotes | disease |
T43 | 366-375 | UBERON:0002298 | denotes | brainstem |
T44 | 407-422 | D000080874 | denotes | synucleinopathy |
T45 | 407-422 | D000080874 | denotes | synucleinopathy |
T46 | 475-478 | PR:P16525 | denotes | Tau |
T47 | 475-478 | PR:000024142 | denotes | Tau |
T48 | 475-478 | PR:P10636 | denotes | Tau |
T49 | 475-478 | PR:000010173 | denotes | Tau |
T50 | 475-478 | PR:P19332 | denotes | Tau |
T52 | 475-478 | PR:P10637 | denotes | Tau |
T51 | 475-478 | CHEBI:36355 | denotes | Tau |
T53 | 522-527 | PR:Q5S006 | denotes | LRRK2 |
T54 | 522-527 | PR:000003033 | denotes | LRRK2 |
T55 | 522-527 | PR:Q5S007 | denotes | LRRK2 |
T56 | 536-550 | D050505 | denotes | mutant protein |
T60 | 543-550 | PR:000000001 | denotes | protein |
T57 | 543-550 | GO:0003675 | denotes | protein |
T61 | 543-550 | SO:0000104 | denotes | protein |
T62 | 584-592 | CHEBI:78059 | denotes | carriers |
T63 | 627-632 | PR:Q5S006 | denotes | LRRK2 |
T64 | 627-632 | PR:000003033 | denotes | LRRK2 |
T65 | 627-632 | PR:Q5S007 | denotes | LRRK2 |
T66 | 683-687 | PR:000005054 | denotes | mice |
T68 | 683-687 | O89094 | denotes | mice |
T67 | 683-687 | D051379 | denotes | mice |
T69 | 683-687 | 10095 | denotes | mice |
T70 | 701-706 | PR:Q5S006 | denotes | LRRK2 |
T71 | 701-706 | PR:000003033 | denotes | LRRK2 |
T72 | 701-706 | PR:Q5S007 | denotes | LRRK2 |
T76 | 737-744 | PR:000000001 | denotes | protein |
T73 | 737-744 | GO:0003675 | denotes | protein |
T77 | 737-744 | SO:0000104 | denotes | protein |
T74 | 737-744 | CHEBI:36080 | denotes | protein |
T75 | 737-744 | CHEBI:11122 | denotes | protein |
T78 | 823-835 | GO:0009405 | denotes | pathogenesis |
T79 | 839-844 | PR:Q5S006 | denotes | LRRK2 |
T80 | 839-844 | PR:000003033 | denotes | LRRK2 |
T81 | 839-844 | PR:Q5S007 | denotes | LRRK2 |
T83 | 878-887 | P37379 | denotes | synuclein |
T82 | 878-887 | D051843 | denotes | synuclein |
T89 | 889-892 | SO:0001449 | denotes | aSN |
T84 | 889-892 | CHEBI:50347 | denotes | aSN |
T85 | 889-892 | CHEBI:50348 | denotes | aSN |
T86 | 889-892 | CHEBI:32654 | denotes | aSN |
T87 | 889-892 | CHEBI:17196 | denotes | aSN |
T88 | 889-892 | CHEBI:22653 | denotes | aSN |
T90 | 944-948 | PR:000005054 | denotes | mice |
T92 | 944-948 | O89094 | denotes | mice |
T91 | 944-948 | D051379 | denotes | mice |
T93 | 944-948 | 10095 | denotes | mice |
T94 | 1006-1011 | PR:Q5S006 | denotes | LRRK2 |
T95 | 1006-1011 | PR:000003033 | denotes | LRRK2 |
T96 | 1006-1011 | PR:Q5S007 | denotes | LRRK2 |
T97 | 1015-1024 | UBERON:0002298 | denotes | brainstem |
T98 | 1068-1073 | PR:Q5S006 | denotes | LRRK2 |
T99 | 1068-1073 | PR:000003033 | denotes | LRRK2 |
T100 | 1068-1073 | PR:Q5S007 | denotes | LRRK2 |
T106 | 1099-1102 | SO:0001449 | denotes | aSN |
T101 | 1099-1102 | CHEBI:50347 | denotes | aSN |
T102 | 1099-1102 | CHEBI:50348 | denotes | aSN |
T103 | 1099-1102 | CHEBI:32654 | denotes | aSN |
T104 | 1099-1102 | CHEBI:17196 | denotes | aSN |
T105 | 1099-1102 | CHEBI:22653 | denotes | aSN |
T107 | 1107-1110 | PR:P16525 | denotes | Tau |
T108 | 1107-1110 | PR:000024142 | denotes | Tau |
T109 | 1107-1110 | PR:P10636 | denotes | Tau |
T110 | 1107-1110 | PR:000010173 | denotes | Tau |
T111 | 1107-1110 | PR:P19332 | denotes | Tau |
T113 | 1107-1110 | PR:P10637 | denotes | Tau |
T112 | 1107-1110 | CHEBI:36355 | denotes | Tau |
T114 | 1173-1188 | D000080874 | denotes | synucleinopathy |
T115 | 1173-1188 | D000080874 | denotes | synucleinopathy |
T116 | 1192-1196 | PR:000005054 | denotes | mice |
T118 | 1192-1196 | O89094 | denotes | mice |
T117 | 1192-1196 | D051379 | denotes | mice |
T119 | 1192-1196 | 10095 | denotes | mice |
T120 | 1230-1235 | PR:Q5S006 | denotes | LRRK2 |
T121 | 1230-1235 | PR:000003033 | denotes | LRRK2 |
T122 | 1230-1235 | PR:Q5S007 | denotes | LRRK2 |
T128 | 1240-1243 | SO:0001449 | denotes | aSN |
T123 | 1240-1243 | CHEBI:50347 | denotes | aSN |
T124 | 1240-1243 | CHEBI:50348 | denotes | aSN |
T125 | 1240-1243 | CHEBI:32654 | denotes | aSN |
T126 | 1240-1243 | CHEBI:17196 | denotes | aSN |
T127 | 1240-1243 | CHEBI:22653 | denotes | aSN |
T129 | 1247-1252 | UBERON:6110636 | denotes | brain |
T130 | 1247-1252 | UBERON:0000955 | denotes | brain |
T131 | 1298-1303 | PR:Q5S006 | denotes | LRRK2 |
T132 | 1298-1303 | PR:000003033 | denotes | LRRK2 |
T133 | 1298-1303 | PR:Q5S007 | denotes | LRRK2 |
T139 | 1364-1367 | SO:0001449 | denotes | aSN |
T134 | 1364-1367 | CHEBI:50347 | denotes | aSN |
T135 | 1364-1367 | CHEBI:50348 | denotes | aSN |
T136 | 1364-1367 | CHEBI:32654 | denotes | aSN |
T137 | 1364-1367 | CHEBI:17196 | denotes | aSN |
T138 | 1364-1367 | CHEBI:22653 | denotes | aSN |
T140 | 1368-1377 | SO:0000902 | denotes | transgene |
T141 | 1386-1393 | D004194 | denotes | disease |
T142 | 1386-1393 | D004194 | denotes | disease |
T143 | 1427-1432 | PR:Q5S006 | denotes | LRRK2 |
T144 | 1427-1432 | PR:000003033 | denotes | LRRK2 |
T145 | 1427-1432 | PR:Q5S007 | denotes | LRRK2 |
T146 | 1512-1527 | D000080874 | denotes | synucleinopathy |
T147 | 1512-1527 | D000080874 | denotes | synucleinopathy |
PubmedHPO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 237-246 | HP_0001300 | denotes | Parkinson |
T2 | 671-675 | HP_0000365 | denotes | dead |
Allie
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
SS1_22615783_1_0 | 141-169 | expanded | denotes | leucine-rich repeat kinase 2 |
SS2_22615783_1_0 | 171-176 | abbr | denotes | LRRK2 |
SS1_22615783_1_1 | 237-256 | expanded | denotes | Parkinson's disease |
SS2_22615783_1_1 | 258-260 | abbr | denotes | PD |
SS1_22615783_5_0 | 876-887 | expanded | denotes | α-synuclein |
SS2_22615783_5_0 | 889-892 | abbr | denotes | aSN |
AE1_22615783_1_0 | SS1_22615783_1_0 | SS2_22615783_1_0 | abbreviatedTo | leucine-rich repeat kinase 2,LRRK2 |
AE1_22615783_1_1 | SS1_22615783_1_1 | SS2_22615783_1_1 | abbreviatedTo | Parkinson's disease,PD |
AE1_22615783_5_0 | SS1_22615783_5_0 | SS2_22615783_5_0 | abbreviatedTo | α-synuclein,aSN |
UseCases_ArguminSci_Discourse
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-93 | DRI_Challenge | denotes | High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. |
T2 | 94-262 | DRI_Challenge | denotes | The G2019S mutation in the multidomain protein leucine-rich repeat kinase 2 (LRRK2) is one of the most frequently identified genetic causes of Parkinson's disease (PD). |
T3 | 263-455 | DRI_Challenge | denotes | Clinically, LRRK2(G2019S) carriers with PD and idiopathic PD patients have a very similar disease with brainstem and cortical Lewy pathology (α-synucleinopathy) as histopathological hallmarks. |
T4 | 456-489 | DRI_Background | denotes | Some patients have Tau pathology. |
T5 | 490-643 | DRI_Background | denotes | Enhanced kinase function of the LRRK2(G2019S) mutant protein is a prime suspect mechanism for carriers to develop PD but observations in LRRK2 knock-out, |
T6 | 644-659 | Token_Label.OUTSIDE | denotes | G2019S knock-in |
T7 | 660-775 | DRI_Background | denotes | and kinase-dead mutant mice suggest that LRRK2 steady-state abundance of the protein also plays a determining role. |
T8 | 776-918 | DRI_Background | denotes | One critical question concerning the molecular pathogenesis in LRRK2(G2019S) PD patients is whether α-synuclein (aSN) has a contributory role. |
T9 | 919-1046 | DRI_Outcome | denotes | To this end we generated mice with high expression of either wildtype or G2019S mutant LRRK2 in brainstem and cortical neurons. |
T10 | 1047-1261 | DRI_Unspecified | denotes | High levels of these LRRK2 variants left endogenous aSN and Tau levels unaltered and did not exacerbate or otherwise modify α-synucleinopathy in mice that co-expressed high levels of LRRK2 and aSN in brain neurons. |
T11 | 1262-1394 | DRI_Outcome | denotes | On the contrary, in some lines high LRRK2 levels improved motor skills in the presence and absence of aSN-transgene-induced disease. |
T12 | 1395-1528 | DRI_Challenge | denotes | Therefore, in many neurons high LRRK2 levels are well tolerated and not sufficient to drive or exacerbate neuronal α-synucleinopathy. |
PubMed_ArguminSci
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 94-262 | DRI_Approach | denotes | The G2019S mutation in the multidomain protein leucine-rich repeat kinase 2 (LRRK2) is one of the most frequently identified genetic causes of Parkinson's disease (PD). |
T2 | 263-455 | DRI_Challenge | denotes | Clinically, LRRK2(G2019S) carriers with PD and idiopathic PD patients have a very similar disease with brainstem and cortical Lewy pathology (α-synucleinopathy) as histopathological hallmarks. |
T3 | 456-489 | DRI_Background | denotes | Some patients have Tau pathology. |
T4 | 490-643 | DRI_Background | denotes | Enhanced kinase function of the LRRK2(G2019S) mutant protein is a prime suspect mechanism for carriers to develop PD but observations in LRRK2 knock-out, |
T5 | 660-775 | DRI_Background | denotes | and kinase-dead mutant mice suggest that LRRK2 steady-state abundance of the protein also plays a determining role. |
T6 | 776-918 | DRI_Background | denotes | One critical question concerning the molecular pathogenesis in LRRK2(G2019S) PD patients is whether α-synuclein (aSN) has a contributory role. |
T7 | 919-1046 | DRI_Outcome | denotes | To this end we generated mice with high expression of either wildtype or G2019S mutant LRRK2 in brainstem and cortical neurons. |
T8 | 1262-1394 | DRI_Outcome | denotes | On the contrary, in some lines high LRRK2 levels improved motor skills in the presence and absence of aSN-transgene-induced disease. |
T9 | 1395-1528 | DRI_Challenge | denotes | Therefore, in many neurons high LRRK2 levels are well tolerated and not sufficient to drive or exacerbate neuronal α-synucleinopathy. |